Harga Saham

Tanggal	Pharma Mar Pendapatan	Pharma Mar EBIT	Pharma Mar Laba
2028e	465,20 Juta. undefined	308,01 Juta. undefined	223,25 Juta. undefined
2027e	228,81 Juta. undefined	99,98 Juta. undefined	131,82 Juta. undefined
2026e	176,75 Juta. undefined	54,00 Juta. undefined	46,67 Juta. undefined
2025e	177,47 Juta. undefined	44,94 Juta. undefined	50,95 Juta. undefined
2024e	159,13 Juta. undefined	1,84 Juta. undefined	4,50 Juta. undefined
2023	158,15 Juta. undefined	-4,10 Juta. undefined	1,14 Juta. undefined
2022	196,34 Juta. undefined	44,44 Juta. undefined	49,36 Juta. undefined
2021	229,83 Juta. undefined	92,35 Juta. undefined	92,86 Juta. undefined
2020	269,96 Juta. undefined	156,21 Juta. undefined	137,26 Juta. undefined
2019	85,82 Juta. undefined	-17,48 Juta. undefined	-11,38 Juta. undefined
2018	108,77 Juta. undefined	-16,03 Juta. undefined	-5,54 Juta. undefined
2017	158,88 Juta. undefined	-19,54 Juta. undefined	-26,75 Juta. undefined
2016	180,95 Juta. undefined	-18,71 Juta. undefined	-24,08 Juta. undefined
2015	193,82 Juta. undefined	11,30 Juta. undefined	6,59 Juta. undefined
2014	174,80 Juta. undefined	20,24 Juta. undefined	13,12 Juta. undefined
2013	141,82 Juta. undefined	18,96 Juta. undefined	11,32 Juta. undefined
2012	161,78 Juta. undefined	14,57 Juta. undefined	6,59 Juta. undefined
2011	177,20 Juta. undefined	23,85 Juta. undefined	4,74 Juta. undefined
2010	161,24 Juta. undefined	-9,52 Juta. undefined	-7,35 Juta. undefined
2009	143,63 Juta. undefined	-21,20 Juta. undefined	-25,88 Juta. undefined
2008	122,85 Juta. undefined	-37,06 Juta. undefined	-40,65 Juta. undefined
2007	99,87 Juta. undefined	-45,33 Juta. undefined	-45,08 Juta. undefined
2006	87,36 Juta. undefined	-48,01 Juta. undefined	-43,82 Juta. undefined
2005	82,39 Juta. undefined	-39,30 Juta. undefined	-37,75 Juta. undefined
2004	94,66 Juta. undefined	-21,85 Juta. undefined	-20,67 Juta. undefined

	Pendapatan	EBIT	Laba
2004	94,66 Juta. EUR	-21,85 Juta. EUR	-20,67 Juta. EUR
2005	82,39 Juta. EUR	-39,30 Juta. EUR	-37,75 Juta. EUR
2006	87,36 Juta. EUR	-48,01 Juta. EUR	-43,82 Juta. EUR
2007	99,87 Juta. EUR	-45,33 Juta. EUR	-45,08 Juta. EUR
2008	122,85 Juta. EUR	-37,06 Juta. EUR	-40,65 Juta. EUR
2009	143,63 Juta. EUR	-21,20 Juta. EUR	-25,88 Juta. EUR
2010	161,24 Juta. EUR	-9,52 Juta. EUR	-7,35 Juta. EUR
2011	177,20 Juta. EUR	23,85 Juta. EUR	4,74 Juta. EUR
2012	161,78 Juta. EUR	14,57 Juta. EUR	6,59 Juta. EUR
2013	141,82 Juta. EUR	18,96 Juta. EUR	11,32 Juta. EUR
2014	174,80 Juta. EUR	20,24 Juta. EUR	13,12 Juta. EUR
2015	193,82 Juta. EUR	11,30 Juta. EUR	6,59 Juta. EUR
2016	180,95 Juta. EUR	-18,71 Juta. EUR	-24,08 Juta. EUR
2017	158,88 Juta. EUR	-19,54 Juta. EUR	-26,75 Juta. EUR
2018	108,77 Juta. EUR	-16,03 Juta. EUR	-5,54 Juta. EUR
2019	85,82 Juta. EUR	-17,48 Juta. EUR	-11,38 Juta. EUR
2020	269,96 Juta. EUR	156,21 Juta. EUR	137,26 Juta. EUR
2021	229,83 Juta. EUR	92,35 Juta. EUR	92,86 Juta. EUR
2022	196,34 Juta. EUR	44,44 Juta. EUR	49,36 Juta. EUR
2023	158,15 Juta. EUR	-4,10 Juta. EUR	1,14 Juta. EUR
2024e	159,13 Juta. EUR	1,84 Juta. EUR	4,50 Juta. EUR
2025e	177,47 Juta. EUR	44,94 Juta. EUR	50,95 Juta. EUR
2026e	176,75 Juta. EUR	54,00 Juta. EUR	46,67 Juta. EUR
2027e	228,81 Juta. EUR	99,98 Juta. EUR	131,82 Juta. EUR
2028e	465,20 Juta. EUR	308,01 Juta. EUR	223,25 Juta. EUR

Pharma Mar Margin Kotor	Pharma Mar Margin Laba	Pharma Mar Margin EBIT	Pharma Mar Margin Laba
2028e	93,92 %	66,21 %	47,99 %
2027e	93,92 %	43,69 %	57,61 %
2026e	93,92 %	30,55 %	26,40 %
2025e	93,92 %	25,32 %	28,71 %
2024e	93,92 %	1,16 %	2,83 %
2023	93,92 %	-2,59 %	0,72 %
2022	93,05 %	22,63 %	25,14 %
2021	92,85 %	40,18 %	40,40 %
2020	94,92 %	57,86 %	50,85 %
2019	93,91 %	-20,36 %	-13,26 %
2018	95,47 %	-14,74 %	-5,09 %
2017	78,01 %	-12,30 %	-16,83 %
2016	75,70 %	-10,34 %	-13,31 %
2015	76,42 %	5,83 %	3,40 %
2014	76,68 %	11,58 %	7,50 %
2013	76,37 %	13,37 %	7,98 %
2012	77,51 %	9,00 %	4,08 %
2011	77,42 %	13,46 %	2,68 %
2010	72,50 %	-5,90 %	-4,56 %
2009	69,95 %	-14,76 %	-18,02 %
2008	68,64 %	-30,16 %	-33,09 %
2007	61,73 %	-45,39 %	-45,14 %
2006	61,76 %	-54,96 %	-50,16 %
2005	65,37 %	-47,71 %	-45,82 %
2004	63,29 %	-23,08 %	-21,83 %

	Margin Kotor	Margin EBIT	Margin Laba
2004	63,29 %	-23,08 %	-21,83 %
2005	65,37 %	-47,71 %	-45,82 %
2006	61,76 %	-54,96 %	-50,16 %
2007	61,73 %	-45,39 %	-45,14 %
2008	68,64 %	-30,16 %	-33,09 %
2009	69,95 %	-14,76 %	-18,02 %
2010	72,50 %	-5,90 %	-4,56 %
2011	77,42 %	13,46 %	2,68 %
2012	77,51 %	9,00 %	4,08 %
2013	76,37 %	13,37 %	7,98 %
2014	76,68 %	11,58 %	7,50 %
2015	76,42 %	5,83 %	3,40 %
2016	75,70 %	-10,34 %	-13,31 %
2017	78,01 %	-12,30 %	-16,83 %
2018	95,47 %	-14,74 %	-5,09 %
2019	93,91 %	-20,36 %	-13,26 %
2020	94,92 %	57,86 %	50,85 %
2021	92,85 %	40,18 %	40,40 %
2022	93,05 %	22,63 %	25,14 %
2023	93,92 %	-2,59 %	0,72 %
2024e	93,92 %	1,16 %	2,83 %
2025e	93,92 %	25,32 %	28,71 %
2026e	93,92 %	30,55 %	26,40 %
2027e	93,92 %	43,69 %	57,61 %
2028e	93,92 %	66,21 %	47,99 %

Tanggal	Pharma Mar Pendapatan per Saham	Pharma Mar EBIT per Saham	Pharma Mar Laba per Saham
2028e	26,08 undefined	0 undefined	12,51 undefined
2027e	12,83 undefined	0 undefined	7,39 undefined
2026e	9,91 undefined	0 undefined	2,62 undefined
2025e	9,95 undefined	0 undefined	2,86 undefined
2024e	8,92 undefined	0 undefined	0,25 undefined
2023	8,83 undefined	-0,23 undefined	0,06 undefined
2022	10,87 undefined	2,46 undefined	2,73 undefined
2021	12,71 undefined	5,11 undefined	5,13 undefined
2020	14,73 undefined	8,52 undefined	7,49 undefined
2019	4,64 undefined	-0,94 undefined	-0,62 undefined
2018	5,90 undefined	-0,87 undefined	-0,30 undefined
2017	8,62 undefined	-1,06 undefined	-1,45 undefined
2016	9,84 undefined	-1,02 undefined	-1,31 undefined
2015	10,51 undefined	0,61 undefined	0,36 undefined
2014	9,51 undefined	1,10 undefined	0,71 undefined
2013	7,70 undefined	1,03 undefined	0,61 undefined
2012	8,81 undefined	0,79 undefined	0,36 undefined
2011	9,59 undefined	1,29 undefined	0,26 undefined
2010	8,79 undefined	-0,52 undefined	-0,40 undefined
2009	7,87 undefined	-1,16 undefined	-1,42 undefined
2008	6,74 undefined	-2,03 undefined	-2,23 undefined
2007	5,56 undefined	-2,52 undefined	-2,51 undefined
2006	4,93 undefined	-2,71 undefined	-2,47 undefined
2005	4,76 undefined	-2,27 undefined	-2,18 undefined
2004	5,51 undefined	-1,27 undefined	-1,20 undefined

	Pendapatan per Saham	EBIT per Saham	Laba per Saham
2004	5,51 EUR	-1,27 EUR	-1,20 EUR
2005	4,76 EUR	-2,27 EUR	-2,18 EUR
2006	4,93 EUR	-2,71 EUR	-2,47 EUR
2007	5,56 EUR	-2,52 EUR	-2,51 EUR
2008	6,74 EUR	-2,03 EUR	-2,23 EUR
2009	7,87 EUR	-1,16 EUR	-1,42 EUR
2010	8,79 EUR	-0,52 EUR	-0,40 EUR
2011	9,59 EUR	1,29 EUR	0,26 EUR
2012	8,81 EUR	0,79 EUR	0,36 EUR
2013	7,70 EUR	1,03 EUR	0,61 EUR
2014	9,51 EUR	1,10 EUR	0,71 EUR
2015	10,51 EUR	0,61 EUR	0,36 EUR
2016	9,84 EUR	-1,02 EUR	-1,31 EUR
2017	8,62 EUR	-1,06 EUR	-1,45 EUR
2018	5,90 EUR	-0,87 EUR	-0,30 EUR
2019	4,64 EUR	-0,94 EUR	-0,62 EUR
2020	14,73 EUR	8,52 EUR	7,49 EUR
2021	12,71 EUR	5,11 EUR	5,13 EUR
2022	10,87 EUR	2,46 EUR	2,73 EUR
2023	8,83 EUR	-0,23 EUR	0,06 EUR
2024e	8,92 EUR	0 EUR	0,25 EUR
2025e	9,95 EUR	0 EUR	2,86 EUR
2026e	9,91 EUR	0 EUR	2,62 EUR
2027e	12,83 EUR	0 EUR	7,39 EUR
2028e	26,08 EUR	0 EUR	12,51 EUR

	Jumlah Saham
2004	17,18 Juta. Aktien
2005	17,31 Juta. Aktien
2006	17,72 Juta. Aktien
2007	17,97 Juta. Aktien
2008	18,22 Juta. Aktien
2009	18,25 Juta. Aktien
2010	18,35 Juta. Aktien
2011	18,48 Juta. Aktien
2012	18,36 Juta. Aktien
2013	18,42 Juta. Aktien
2014	18,39 Juta. Aktien
2015	18,44 Juta. Aktien
2016	18,38 Juta. Aktien
2017	18,44 Juta. Aktien
2018	18,44 Juta. Aktien
2019	18,50 Juta. Aktien
2020	18,33 Juta. Aktien
2021	18,09 Juta. Aktien
2022	18,06 Juta. Aktien
2023	17,92 Juta. Aktien
2024e	17,92 Juta. Aktien
2025e	17,92 Juta. Aktien
2026e	17,92 Juta. Aktien
2027e	17,92 Juta. Aktien
2028e	17,92 Juta. Aktien

Tanggal	Pharma Mar Dividen
2028e	0,77 undefined
2027e	0,77 undefined
2026e	0,77 undefined
2025e	0,77 undefined
2024e	0,77 undefined
2023	0,65 undefined
2022	0,65 undefined
2021	0,60 undefined
2020	0,48 undefined
2008	0,06 undefined
2007	0,06 undefined
2004	0,12 undefined

	Dividen	Dividen (Estimasi)
2004	0,12 EUR	0 EUR
2005	0 EUR	0 EUR
2006	0 EUR	0 EUR
2007	0,06 EUR	0 EUR
2008	0,06 EUR	0 EUR
2009	0 EUR	0 EUR
2010	0 EUR	0 EUR
2011	0 EUR	0 EUR
2012	0 EUR	0 EUR
2013	0 EUR	0 EUR
2014	0 EUR	0 EUR
2015	0 EUR	0 EUR
2016	0 EUR	0 EUR
2017	0 EUR	0 EUR
2018	0 EUR	0 EUR
2019	0 EUR	0 EUR
2020	0,48 EUR	0 EUR
2021	0,60 EUR	0 EUR
2022	0,65 EUR	0 EUR
2023	0,65 EUR	0 EUR
2024e	0 EUR	0,77 EUR
2025e	0 EUR	0,77 EUR
2026e	0 EUR	0,77 EUR
2027e	0 EUR	0,77 EUR
2028e	0 EUR	0,77 EUR

Tanggal	Pharma Mar Rasio Pembayaran Dividen
2028e	17,07 %
2027e	16,92 %
2026e	16,18 %
2025e	18,09 %
2024e	16,49 %
2023	13,97 %
2022	23,81 %
2021	11,70 %
2020	6,41 %
2019	13,97 %
2018	13,97 %
2017	13,97 %
2016	13,97 %
2015	13,97 %
2014	13,97 %
2013	13,97 %
2012	13,97 %
2011	13,97 %
2010	13,97 %
2009	13,97 %
2008	-2,69 %
2007	-2,39 %
2006	13,97 %
2005	13,97 %
2004	-9,80 %

	Rasio Pembayaran Dividen
2004	-9,80 %
2005	13,97 %
2006	13,97 %
2007	-2,39 %
2008	-2,69 %
2009	13,97 %
2010	13,97 %
2011	13,97 %
2012	13,97 %
2013	13,97 %
2014	13,97 %
2015	13,97 %
2016	13,97 %
2017	13,97 %
2018	13,97 %
2019	13,97 %
2020	6,41 %
2021	11,70 %
2022	23,81 %
2023	13,97 %
2024e	16,49 %
2025e	18,09 %
2026e	16,18 %
2027e	16,92 %
2028e	17,07 %

Tanggal	Estimasi EPS	EPS-Actual	Kuartal Laporan
30/6/2018	-0,36	0,12 (133,00 %)	2018 Q2

%	Nama	Saham	Perubahan	Tanggal
6,25 %	Fernandez Sousa Faro (Jose Maria)	1.114.147	0	10/8/2023
5,35 %	Andrade Detrell (Montserrat)	954.460	0	10/8/2023
5,20 %	Ortega Mera (Sandra)	927.705	0	10/8/2023
5,15 %	Fernandez Puentes (Pedro Francisco)	917.979	0	10/8/2023
2,06 %	The Vanguard Group, Inc.	368.173	-19.507	31/3/2024
1,17 %	BlackRock Institutional Trust Company, N.A.	208.023	170	31/3/2024
1,13 %	Norges Bank Investment Management (NBIM)	201.527	-59.564	31/12/2023
1,10 %	Redwheel	196.406	0	10/8/2023
0,49 %	Dimensional Fund Advisors, L.P.	86.609	0	31/3/2024
0,39 %	BlackRock Advisors (UK) Limited	68.754	-1.593	31/3/2024
0,34 %	Jupiter Asset Management Ltd.	61.134	0	31/12/2023
0,30 %	State Street Global Advisors (US)	54.116	0	31/3/2024
0,29 %	Old Mutual Investment Group (South Africa) (Pty) Limited	51.019	-1.950	30/6/2023
0,18 %	Caixabank Asset Management SGIIC, S.A.U.	31.715	29.026	31/12/2023
0,18 %	Credit Suisse Funds AG	31.709	-6.600	29/2/2024
0,13 %	Charles Schwab Investment Management, Inc.	22.378	-3.975	31/3/2024
0,12 %	Mellon Investments Corporation	20.914	280	31/3/2024
0,11 %	DWS Investment GmbH	18.887	1.024	29/2/2024
0,09 %	Legal & General Investment Management Ltd.	16.778	-5.388	31/3/2024
0,09 %	California State Teachers Retirement System	15.973	-66	30/6/2023
0,08 %	Urquijo Gestión, S.A., S.G.I.I.C., Sociedad Unipersonal	15.000	0	31/12/2023
0,07 %	Amundi Asset Management, SAS	12.518	0	31/3/2024
0,07 %	Geode Capital Management, L.L.C.	12.054	0	29/2/2024
0,07 %	Nuveen LLC	11.994	0	31/3/2024
0,06 %	Serra Rexach (Eduardo)	11.013	0	31/12/2022
0,06 %	Dimensional Fund Advisors, Ltd.	10.007	528	31/1/2024
0,04 %	Credit Suisse Asset Management (Schweiz) AG	8.019	0	29/2/2024
0,04 %	Consultinvest Asset Management SGR S.p.A.	7.500	0	30/9/2023
0,04 %	Andbank Wealth Management, SGIIC, S.A.U.	6.930	0	31/8/2023
0,03 %	UBS Asset Management (Switzerland)	5.288	0	31/3/2024
0,03 %	State Street Global Advisors Ireland Limited	5.046	-1.066	31/3/2024
0,03 %	Zürcher Kantonalbank (Asset Management)	4.873	0	31/1/2024
0,03 %	BlackRock Asset Management Canada Limited	4.494	0	31/3/2024
0,02 %	BlackRock Financial Management, Inc.	4.272	-3.397	30/11/2023
0,02 %	Florida State Board of Administration	4.243	-4.204	30/9/2022
0,02 %	Mercer Global Investments Management Ltd	4.088	0	31/3/2024
0,02 %	Mirae Asset Global Investments (USA) LLC	3.649	95	31/3/2024
0,02 %	Irish Life Investment Managers Ltd.	3.472	319	31/3/2024
0,02 %	Northern Trust Global Investments Limited	3.402	0	31/12/2023
0,02 %	Caja Laboral Gestión S.G.I.I.C., S.A.	3.329	2.886	31/12/2023
0,02 %	Unigest, S.G.I.I.C., S.A.	3.095	1.321	31/3/2023
0,01 %	KLP Fondsforvaltning AS	2.626	0	29/2/2024
0,01 %	Vanguard Investments Australia Ltd.	2.578	-2	29/2/2024
0,01 %	Renta 4 Gestora, S.G.I.I.C., S.A.	2.500	-1.731	31/12/2023
0,01 %	ANDBANK Asset Management Luxembourg SA	2.100	0	30/6/2023
0,01 %	Greiff capital management AG	1.961	-499	31/3/2023
0,01 %	BlackRock Investment Management (UK) Ltd.	1.866	0	31/12/2023
0,01 %	Hernandez Rodriguez (Blanca)	1.855	-1.816	31/12/2022
0,01 %	Nykredit Bank AS	1.092	126	29/2/2024
0,01 %	Hussman Strategic Advisors, Inc.	1.000	0	31/3/2023
0,01 %	UniCredit International Bank (Luxembourg) S.A.	981	981	31/12/2022
0,00 %	Pictet Asset Management Ltd.	850	0	30/11/2023
0,00 %	Euroagentes Gestión S.G.I.I.C., S.A.	846	846	30/9/2023
0,00 %	Inversis Gestión, S.A., SGIIC	832	294	31/3/2023
0,00 %	DFA Australia Ltd.	715	-311	31/12/2023
0,00 %	Vanguard Global Advisers LLC	688	0	31/3/2024
0,00 %	UBS Asset Management (UK) Ltd.	520	0	29/2/2024
0,00 %	Danske Bank Asset Management	461	-3.906	31/12/2023
0,00 %	Dimensional Fund Advisors Canada ULC	320	0	30/11/2023
0,00 %	Sumitomo Mitsui Trust Asset Management Co., Ltd.	295	-5	31/3/2023
0,00 %	Anfield Capital Management, LLC	263	0	31/12/2022
0,00 %	American Century Investment Management, Inc.	261	0	31/3/2024
0,00 %	Sanchez-Yebra Alonso (Rosa Maria)	184	184	31/12/2022
0,00 %	DBX Advisors LLC.	83	-10	29/2/2024
0,00 %	BMO Asset Management Inc.	28	0	30/11/2023
0 %	Rayliant Global Advisors	0	-3.001	30/9/2022
0 %	Finlabo SIM S.p. A.	0	-5.500	31/8/2022
0 %	Legato Capital Management LLC	0	-3.481	30/9/2022
0 %	UNIQA Towarzystwo Funduszy Inwestycyjnych S. A	0	-4.900	31/12/2022
0 %	Aramea Asset Management AG	0	-9.000	31/3/2023
0 %	Perinvest (UK) Ltd.	0	-5.260	31/12/2022
0 %	BG Fund Management Luxembourg S.A.	0	-5.857	31/1/2024
0 %	Mediolanum International Funds Limited	0	-855	30/6/2023
0 %	Gesiuris Asset Management S.G.I.I.C., S.A.	0	-2.785	30/6/2023
0 %	FIL Investment Management (Australia) Limited	0	-221	31/12/2022
0 %	SEI Investments Management Corporation	0	-3.994	31/5/2023
0 %	AMUNDI IBERIA SGIIC SA	0	-13.846	30/6/2023
0 %	Montepio Gestão de Activos - SGFI, S.A.	0	-833	30/4/2023
0 %	Imantia Capital	0	-562	31/12/2023
0 %	Gescooperativo, S.A., S.G.I.I.C.	0	-2.000	30/6/2023
0 %	Santander Asset Management	0	-276.581	30/6/2023
0 %	Sabadell Asset Management, S.A., S.G.I.I.C., Sociedad Unipersonal	0	-61.016	30/6/2023
0 %	Allianz Popular Asset Management, SGIIC, S.A.	0	-538	31/12/2023
0 %	BBVA Asset Management, S.A., S.G.I.I.C.	0	-12.755	30/6/2023
0 %	GVC Gaesco Gestión SGIIC S.A.	0	-2.600	31/3/2023
0 %	FIL Investment Management (Hong Kong) Limited	0	-2.531	30/11/2022
0 %	Baillie Gifford & Co.	0	-3.817	31/1/2024
0 %	Fidelity International	0	-19.282	31/12/2022
0 %	Union Bancaire Privée	0	-3.806	31/8/2023
0 %	Handelsbanken Kapitalförvaltning AB	0	-1.464	31/5/2023
0 %	Robeco Institutional Asset Management B.V.	0	-1.797	30/4/2023
0 %	Rockefeller Capital Management	0	-306	31/3/2024
0 %	Thrivent Asset Management, LLC	0	-2.343	31/10/2023
0 %	Lazard Asset Management, L.L.C.	0	-579	31/8/2022
0 %	Victory Capital Management Inc.	0	-1.482	30/6/2023
0 %	Northern Trust Investments, Inc.	0	-824	31/12/2023
0 %	AllianceBernstein L.P.	0	-44.165	30/4/2023
0 %	Goldman Sachs Asset Management, L.P.	0	-31.393	30/4/2023
0 %	Avantis Investors	0	-29.153	30/6/2023

What values and corporate philosophy does Pharma Mar represent?

Pharma Mar SA represents a set of core values and corporate philosophy that drive its operations. The company focuses on developing innovative therapies in the field of oncology and the treatment of other serious diseases. With a commitment to scientific excellence, Pharma Mar SA aims to create impactful solutions that improve patients' lives. Through strategic collaborations and continuous research, the company strives to deliver cutting-edge pharmaceutical products. Pharma Mar SA's dedication to ethical practices, transparency, and sustainability further reinforces its commitment to stakeholders and the global healthcare community.

In which countries and regions is Pharma Mar primarily present?

Pharma Mar SA is primarily present in several countries and regions. The company has a strong presence in Spain, where it is based and operates its headquarters. Additionally, Pharma Mar SA has expanded its operations to various international markets, including the United States, Germany, Italy, France, and Switzerland. With a global presence, Pharma Mar SA strives to bring its innovative pharmaceutical products and treatments to patients worldwide.

What significant milestones has the company Pharma Mar achieved?

Pharma Mar SA, a leading pharmaceutical company, has achieved significant milestones in its remarkable journey. The company's innovative approach and dedication to drug discovery have yielded remarkable results. Pharma Mar SA's milestones include successful clinical trials for their flagship drugs, receiving regulatory approvals, and securing strategic partnerships with renowned pharmaceutical companies. Furthermore, the company's consistent commitment to scientific research and development has resulted in groundbreaking discoveries that have revolutionized the treatment of various diseases. Through their remarkable achievements, Pharma Mar SA has solidified its position as a pioneering force in the pharmaceutical industry and continues to make invaluable contributions towards improving global healthcare.

What is the history and background of the company Pharma Mar?

Pharma Mar SA is a leading biopharmaceutical company with a rich history and background. Established in 1986, the company is headquartered in Madrid, Spain. Pharma Mar SA focuses on the research, development, and commercialization of innovative marine-derived drugs to address various oncology and rare diseases. With a strong commitment to scientific excellence, Pharma Mar SA has built a diverse pipeline of potential therapies, leveraging the unique properties of marine organisms. The company has garnered global recognition for its breakthrough discovery of marine-derived compounds, including the development of Aplidin® (plitidepsin), a promising anticancer agent undergoing clinical trials. Pharma Mar SA continues to push boundaries in the pharmaceutical industry, striving to improve patients' lives worldwide.

Who are the main competitors of Pharma Mar in the market?

The main competitors of Pharma Mar SA in the market include other pharmaceutical companies operating in the same field and targeting similar market segments. Some notable competitors of Pharma Mar SA may include (examples only, not an exhaustive list): AstraZeneca, Novartis, Roche Holding, Pfizer, and Johnson & Johnson. These companies also focus on researching, developing, and marketing pharmaceutical products, including therapies and treatment options.

In which industries is Pharma Mar primarily active?

Pharma Mar SA is primarily active in the pharmaceutical industry.

What is the business model of Pharma Mar?

The business model of Pharma Mar SA revolves around the research, development, and commercialization of innovative marine-derived pharmaceutical products. Pharma Mar specializes in the development of therapies derived from marine resources, particularly marine microorganisms. By harnessing the therapeutic potential of the sea, the company aims to bring effective treatments to patients suffering from various diseases, including cancer. With a focus on oncology, Pharma Mar seeks to address unmet medical needs and improve patients' lives globally. Through strategic partnerships, clinical trials, and ongoing research, Pharma Mar continues to drive advancements in the field of marine-derived pharmaceuticals.

Berapa KGV dari Pharma Mar 2024?

Rasio P/E Pharma Mar adalah 157,03.

KUV apa yang dimiliki oleh Pharma Mar 2024?

Rasio KUV dari Pharma Mar adalah 4,44.

Skor Kualitas AlleAktien apa yang dimiliki oleh Pharma Mar?

Skor Kualitas AlleAktien untuk Pharma Mar adalah 1/10.

Berapa jumlah pendapatan dari Pharma Mar 2024?

Omset diharapkan Pharma Mar adalah 159,13 Juta. EUR.

Berapa besar keuntungan dari Pharma Mar 2024?

Laba diharapkan Pharma Mar adalah 4,50 Juta. EUR.

Apa yang dilakukan Pharma Mar?

Pharma-Mar SA is a Spanish pharmaceutical company specializing in the development and marketing of cancer therapies. The company was founded in 1986 and is based in Colmenar Viejo, near Madrid. The company consists of two different business areas: Oncology and Consumer Healthcare. The Oncology division focuses on the development and marketing of innovative cancer drugs based on marine compounds, while the Consumer Healthcare division distributes over-the-counter drugs and cosmetic products. The company's business model is based on a strong research and development department that specializes in the exploration and development of cancer drugs based on marine compounds. They also collaborate with other pharmaceutical companies and research institutions to advance the research and development of cancer drugs. The company has a strong presence in international markets and has distribution partnerships in Europe, America, and Asia, allowing them to market their products worldwide and increase their revenue. Overall, Pharma-Mar SA is dedicated to the research, development, and distribution of cancer drugs, as well as over-the-counter drugs and cosmetic products.

Berapa besar dividen Pharma Mar?

Pharma Mar membayarkan dividen sebesar 0,65 EUR yang dibagi melalui pembayaran dalam setahun.

Berapa kali Pharma Mar membayar dividen?

Dividen untuk Pharma Mar saat ini tidak dapat dihitung atau perusahaan tidak membagikan dividen.

Apa itu ISIN Pharma Mar?

ISIN dari Pharma Mar adalah ES0169501022.

Apa itu Pharma Mar WKN?

WKN dari Pharma Mar adalah A2P9YT.

Apa itu Ticker Pharma Mar?

Ticker dari Pharma Mar adalah PHM.MC.

Berapa banyak Dividen yang dibayarkan oleh Pharma Mar?

Dalam 12 bulan terakhir, Pharma Mar membayar dividen sebesar 0,65 EUR . Ini setara dengan yield dividen sekitar 1,65 %. Untuk 12 bulan mendatang, Pharma Mar diperkirakan akan membayar dividen sebesar 0,77 EUR.

Berapa tingkat dividen dari Pharma Mar?

Imbal hasil dividen dari Pharma Mar saat ini adalah 1,65 %.

Kapan Pharma Mar membayar dividen?

Pharma Mar membayar dividen setiap kuartal. Dividen ini dibayarkan pada bulan Mei, Agustus, Juli, Juli.

Seberapa aman dividen dari Pharma Mar?

Pharma Mar membayar dividen setiap tahun dalam 9 tahun terakhir.

Berapa besar dividen dari Pharma Mar?

Untuk 12 bulan ke depan, diperkirakan akan ada dividen sebesar 0,77 EUR. Ini setara dengan yield dividen sebesar 1,94 %.

Di sektor manakah Pharma Mar berada?

Pharma Mar dikelompokkan dalam sektor 'Kesehatan'.

Wann musste ich die Aktien von Pharma Mar kaufen, um die vorherige Dividende zu erhalten?

Untuk menerima dividen terakhir dari Pharma Mar tanggal 14/6/2024 sejumlah 0,65 EUR, Anda harus memiliki saham tersebut di portofolio sebelum tanggal Ex-Tag pada 12/6/2024.

Kapan Pharma Mar membayar dividen terakhir?

Pembayaran dividen terakhir dilakukan pada 14/6/2024.

Berapa besarnya dividen dari Pharma Mar pada tahun 2023?

Pada tahun 2023, Pharma Mar 0,65 EUR telah dibayarkan sebagai dividen.

Dalam mata uang apa Pharma Mar membayar dividen?

Dividen dari Pharma Mar dibayarkan dalam EUR.

1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024e	2025e	2026e	2027e	2028e
32,00	33,00	36,00	39,00	48,00	56,00	84,00	69,00	76,00	94,00	82,00	87,00	99,00	122,00	143,00	161,00	177,00	161,00	141,00	174,00	193,00	180,00	158,00	108,00	85,00	269,00	229,00	196,00	158,00	159,00	177,00	176,00	228,00	465,00
-	3,13	9,09	8,33	23,08	16,67	50,00	-17,86	10,14	23,68	-12,77	6,10	13,79	23,23	17,21	12,59	9,94	-9,04	-12,42	23,40	10,92	-6,74	-12,22	-31,65	-21,30	216,47	-14,87	-14,41	-19,39	0,63	11,32	-0,56	29,55	103,95
71,88	69,70	66,67	69,23	72,92	91,07	100,00	117,39	117,11	62,77	64,63	60,92	61,62	68,85	69,93	72,05	77,40	77,64	76,60	77,01	76,68	75,56	77,85	95,37	94,12	95,17	93,01	92,86	93,67	-	-	-	-	-
23,00	23,00	24,00	27,00	35,00	51,00	84,00	81,00	89,00	59,00	53,00	53,00	61,00	84,00	100,00	116,00	137,00	125,00	108,00	134,00	148,00	136,00	123,00	103,00	80,00	256,00	213,00	182,00	148,00	0	0	0	0	0
1,00	3,00	1,00	3,00	5,00	4,00	-4,00	0	-23,00	-21,00	-39,00	-48,00	-45,00	-37,00	-21,00	-9,00	23,00	14,00	18,00	20,00	11,00	-18,00	-19,00	-16,00	-17,00	156,00	92,00	44,00	-4,00	1,00	44,00	53,00	99,00	308,00
3,13	9,09	2,78	7,69	10,42	7,14	-4,76	-	-30,26	-22,34	-47,56	-55,17	-45,45	-30,33	-14,69	-5,59	12,99	8,70	12,77	11,49	5,70	-10,00	-12,03	-14,81	-20,00	57,99	40,17	22,45	-2,53	0,63	24,86	30,11	43,42	66,24
1,00	1,00	1,00	3,00	9,00	12,00	9,00	4,00	2,00	-20,00	-37,00	-43,00	-45,00	-40,00	-25,00	-7,00	4,00	6,00	11,00	13,00	6,00	-24,00	-26,00	-5,00	-11,00	137,00	92,00	49,00	1,00	4,00	50,00	46,00	131,00	223,00
-	-	-	200,00	200,00	33,33	-25,00	-55,56	-50,00	-1.100,00	85,00	16,22	4,65	-11,11	-37,50	-72,00	-157,14	50,00	83,33	18,18	-53,85	-500,00	8,33	-80,77	120,00	-1.345,45	-32,85	-46,74	-97,96	300,00	1.150,00	-8,00	184,78	70,23
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
14,24	14,24	14,24	14,24	11,30	12,58	17,32	17,40	17,40	17,18	17,31	17,72	17,97	18,22	18,25	18,35	18,48	18,36	18,42	18,39	18,44	18,38	18,44	18,44	18,50	18,33	18,09	18,06	17,92	0	0	0	0	0
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
-23,00	-21,00	-39,00	-48,00	-46,00	-42,00	-26,00	-14,00	1,00	-1,00	13,00	14,00	5,00	-24,00	-22,00	-7,00	-23,00	145,00	95,00	43,00	-3,00
18,00	5,00	5,00	5,00	5,00	5,00	5,00	5,00	5,00	5,00	4,00	5,00	6,00	7,00	7,00	6,00	6,00	7,00	5,00	5,00	5,00
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
-16,00	5,00	11,00	-6,00	-7,00	-1,00	-3,00	-12,00	-9,00	3,00	2,00	-4,00	-7,00	2,00	8,00	-10,00	-16,00	115,00	-72,00	-27,00	-16,00
-51,00	-9,00	-10,00	-6,00	0	3,00	2,00	0	-2,00	-1,00	-3,00	7,00	6,00	6,00	6,00	-5,00	7,00	10,00	-2,00	15,00	1,00
4,00	0	0	0	0	1,00	0	0	0	0	0	6,00	6,00	5,00	5,00	4,00	2,00	3,00	3,00	2,00	2,00
0	0	0	0	0	0	2,00	0	0	0	0	0	0	0	-3,00	-7,00	0	9,00	7,00	-2,00	-16,00
-71,00	-21,00	-33,00	-56,00	-49,00	-35,00	-22,00	-21,00	-4,00	6,00	16,00	22,00	11,00	-8,00	-1,00	-16,00	-26,00	278,00	25,00	38,00	-13,00
-18,00	-3,00	-2,00	-4,00	-3,00	-8,00	-5,00	-3,00	-3,00	-2,00	-2,00	-10,00	-9,00	-6,00	-4,00	-2,00	-3,00	-3,00	-7,00	-8,00	-15,00
21,00	-17,00	-59,00	52,00	-19,00	27,00	-6,00	-3,00	5,00	0	10,00	-22,00	-28,00	13,00	5,00	22,00	32,00	-119,00	18,00	10,00	-43,00
39,00	-14,00	-57,00	57,00	-15,00	36,00	-1,00	0	8,00	2,00	12,00	-12,00	-19,00	19,00	10,00	24,00	35,00	-116,00	26,00	19,00	-27,00
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
18,00	3,00	-1,00	-4,00	10,00	16,00	13,00	17,00	1,00	-13,00	-17,00	1,00	0	1,00	3,00	-9,00	-12,00	-31,00	-9,00	-8,00	-1,00
0	0	54,00	25,00	40,00	-7,00	9,00	4,00	0	0	0	-2,00	6,00	0	0	0	1,00	-33,00	-7,00	7,00	-19,00
15,00	18,00	52,00	20,00	50,00	9,00	28,00	28,00	-11,00	-18,00	-23,00	-5,00	8,00	1,00	5,00	-7,00	-11,00	-73,00	-27,00	-13,00	-32,00
-1,00	14,00	0	0	0	0	5,00	5,00	-13,00	-5,00	-5,00	-4,00	2,00	0	1,00	3,00	0	0	0	0	0
-2,00	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-8,00	-10,00	-11,00	-11,00
-34,00	-20,00	-40,00	17,00	-17,00	1,00	0	3,00	-10,00	-12,00	4,00	-5,00	-8,00	6,00	9,00	-1,00	-5,00	78,00	17,00	36,00	-89,00
-89,96	-24,78	-35,28	-60,76	-53,02	-44,23	-28,31	-24,99	-7,34	4,29	14,25	12,61	1,88	-14,51	-6,12	-18,72	-30,05	275,94	17,87	29,47	-29,40
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Emisi Langsung.	1.157
Emisi tidak langsung dari energi yang dibeli.	1.371
Emisi tidak langsung dalam rantai nilai	5.765
Emisi CO₂	2.528
Strategi Reduksi CO₂	✅
Energi Batubara	❌
Energi Nuklir	❌
Percobaan pada hewan	✅
Bulu & Kulit	—
Pestisida	—
Minyak Sawit	—
Tembakau	❌
Bioteknologi	❌
Konsep Iklim	—
Pengelolaan Hutan Berkelanjutan	—
Peraturan Daur Ulang	✅
Kemasan Ramah Lingkungan	❌
Bahan berbahaya	✅
Konsumsi dan Efisiensi Bahan Bakar	❌
Penggunaan dan Efisiensi Air	✅

Persentase Karyawan Wanita	61
Proporsi Wanita dalam Manajemen	—
Porsi Karyawan Asia	—
Porsi Manajemen Asia	—
Proporsi Karyawan Hispanik/Latino	—
Porsi Manajemen Hispanik/Latino	—
Porsi Karyawan Berkulit Hitam	—
Porsi Manajemen Hitam	—
Proporsi Karyawan Kulit Putih	—
Porsi manajemen berkulit putih	—
Konten Dewasa	❌
Alkohol	❌
Pertahanan	—
Senjata api	❌
Judi	❌
Kontrak Militer	❌
Konsep Hak Asasi Manusia	✅
Konsep Perlindungan Data	—
Kesehatan dan Keselamatan Kerja	✅
Katolik	✅

Laporan Keberlanjutan	✅
Stakeholder-Engagement	❌
Kebijakan Pemanggilan Kembali	❌
Hukum Anti Monopoli	❌

Bursa	Pharma Mar Ticker
BME	PHM.MC
DÜSSELDORF	PMRA.DU
FRANKFURT	PMRA.F
LONDON	0RC6.L
MADRID	PHM.MC
MÜNCHEN	PMRA.MU
PNK	PHMMF

Pharma Mar Ticker	Pharma Mar FIGI
PHM:SM	BBG000F3LRQ5
PHM:SQ	BBG00BBLCS10
PHME:PO	BBG00BBVNW62
PHM1N:MM	BBG00BBVNWW3
PHM1N:MF	BBG00BBVNWX2
PHME:B3	BBG00BBVSVX9
PHME:L3	BBG00BBVT2X2
PHME:IX	BBG00BBVTHT4
PHME:EB	BBG00BBVTSR2
PHMMF:US	BBG00BBVVVW6
PHMMF:PQ	BBG00BBVVWB7
PHMMF:UV	BBG00BBVVWC6
PMRA:GR	BBG00BBVX640
PMRA:GF	BBG00BBVX668
PMRA:GD	BBG00BBVX686
PMRA:GS	BBG00BBVX6D0
PMRA:GM	BBG00BBVX6G7
PMRA:GB	BBG00BBVX6K2
PHM2EUR:EO	BBG00BC6MW94
PHM2EUR:XH	BBG00BC6MWD9
PHM2EUR:XF	BBG00BC6MWG6
PHM2EUR:XE	BBG00BC6MWJ3
PHM2EUR:XJ	BBG00BC6MWK1
PHM2EUR:XL	BBG00BC6MWL0
PHM2EUR:XG	BBG00BC6MWM9
PHM2EUR:XO	BBG00BC6MWN8
PHM2EUR:XA	BBG00BC6MWT2
PHM2EUR:E1	BBG00BC6MWV9
PHM2EUR:XT	BBG00BC6MWW8
PHM2EUR:XW	BBG00BC6MWX7
PHM2EUR:XU	BBG00BC6MWY6
PHM2EUR:XV	BBG00BC6MWZ5
PHM2EUR:EU	BBG00BC6MX10
PHME:S1	BBG00BLYVNR3
PHM2USD:EO	BBG00BQXJSL9
PHM2USD:XH	BBG00BQXJSP5
PHM2USD:XF	BBG00BQXJSR3
PHM2USD:XE	BBG00BQXJST1
PHM2USD:XJ	BBG00BQXJSV8
PHM2USD:XL	BBG00BQXJSW7
PHM2USD:XG	BBG00BQXJSX6
PHM2USD:XO	BBG00BQXJSY5
PHM2USD:XA	BBG00BQXJT37
PHM2USD:E1	BBG00BQXJT46
PHM2USD:XT	BBG00BQXJT55
PHM2USD:XW	BBG00BQXJT64
PHM2USD:XU	BBG00BQXJT73
PHM2USD:XV	BBG00BQXJT82
PHM2USD:EU	BBG00BQXJTC7
PHME:BQ	BBG00CWZT0V4
PMRA:QT	BBG00D8M3XH0
PHME:QX	BBG00F16YBH1
PMRA:TH	BBG00GXJ23L4
PHM2EUR:XM	BBG00J9WNBR9
PHM2EUR:XX	BBG00JN8G0V3
PHM2USD:XX	BBG00JN8GG75
PHM1N:MU	BBG00JX0QJT0
PHM2GBX:EO	BBG00KVTPH57
PHM2GBX:XH	BBG00KVTPH84
PHM2GBX:XF	BBG00KVTPHB0
PHM2GBX:XE	BBG00KVTPHD8
PHM2GBX:XJ	BBG00KVTPHF6
PHM2GBX:XL	BBG00KVTPHG5
PHM2GBX:XG	BBG00KVTPHH4
PHM2GBX:XO	BBG00KVTPHJ2
PHM2GBX:XA	BBG00KVTPHN7
PHM2GBX:E1	BBG00KVTPHP5
PHM2GBX:XT	BBG00KVTPHQ4
PHM2GBX:XW	BBG00KVTPHR3
PHM2GBX:XU	BBG00KVTPHS2
PHM2GBX:XV	BBG00KVTPHT1
PHM2GBX:XM	BBG00KVTPHV8
PHM2GBX:XQ	BBG00KVTPHX6
PHM2GBX:XX	BBG00KVTPHY5
PHM2GBX:XZ	BBG00KVTPHZ4
PHM2GBX:EU	BBG00KVTPJ17
PHMEUR:T2	BBG00N0091J6
PHME:QE	BBG00NL2WH99
PHME:T1	BBG00NLK4JY8
PHME:I2	BBG00NQCR2H2
PHMEUR:WT	BBG00NR92YN8
PHM2EUR:X2	BBG00Q5MNPH9
PHM2GBX:EP	BBG00WFC2YB7
PHM2GBX:EZ	BBG00WFC2YH1
PHME:TQ	BBG00XH531T0
PHM2USD:EP	BBG00XH531Y4
PHM2USD:EZ	BBG00XH53209
PMRA:GZ	BBG00XRJ4QN9
0RC6:LO	BBG00Y63DGS2
PHME:L1	BBG00Y92LFM0
PHME:S4	BBG00YJ81176
PMRA:LA	BBG018H9F9Z9
PMRA:LU	BBG018J32BQ9

Lakukan investasi terbaik dalam hidupmu fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Pharma Mar Saham Saham Dividen, Harga, Proyeksi, Forum, Target Harga dan Berita Pharma Mar ariva, Pharma Mar onvista, Pharma Mar finanzen.net, Pharma Mar aktienfinder, Pharma Mar marketscreener, Pharma Mar marketwatch, Pharma Mar bloomberg, Pharma Mar handelsblatt, Pharma Mar wiwo, Pharma Mar forum

Harga saham

Harga saham

TickerPHM.MC

ISINES0169501022

WKNA2P9YT

Pharma Mar Saham Pendapatan, EBIT, Laba ES0169501022 · A2P9YT

Pendapatan, Laba & EBIT

Pemahaman Pendapatan, EBIT dan Penghasilan

Analisis Tahunan dan Perbandingan

Memanfaatkan Harapan Investasi

Wawasan Investasi

Pharma Mar Omzet, Laba, dan Histori EBIT

Pharma Mar Saham Kennzahlen

GuV

Pendapatan dan Pertumbuhan

Margin Bruto

EBIT dan Margin EBIT

Pendapatan dan Pertumbuhan

Saham yang Beredar

Interpretasi Perbandingan Tahunan

Ekspektasi dan Prakiraan

Neraca

Memahami Neraca

Aset

Kewajiban

Ekuitas

Analisis Tahun Demi Tahun

Interpretasi Data

Pharma Mar Saham Marjin ES0169501022 · A2P9YT

Margen

Pemahaman Margin Kotor

Analisis Margin EBIT

Wawasan Margin Penjualan

Menginterpretasikan Harapan

Analisis Komparatif

Pharma Mar Sejarah Margin

Pharma Mar Saham Pendapatan, EBIT, Laba per Saham ES0169501022 · A2P9YT

Pendapatan, EBIT dan Laba per Saham

Pendapatan per Saham

EBIT per Saham

Pendapatan per Saham

Nilai yang Diharapkan

Pharma Mar Pendapatan, Laba, dan EBIT per Saham Sejarah

Pharma Mar Saham dan Analisis Saham

Pharma Mar Penilaian berdasarkan KGV, EBIT, dan KUV historis

Pharma Mar Jumlah Saham ES0169501022 · A2P9YT

Pendapatan, EBIT dan Laba per Saham

Pendapatan per Saham

EBIT per Saham

Pendapatan per Saham

Nilai yang Diharapkan

Pharma Mar Pemecahan Saham

Pharma Mar Dividen Saham ES0169501022 · A2P9YT

Dividen

Tinjauan atas Dividen

Interpretasi dan Penggunaan

Strategi Investasi

Pharma Mar Sejarah Dividen

Pharma Mar Rasio Pembayaran Dividen ES0169501022 · A2P9YT

Ausschüttungsquote

Apa itu rasio pembagian dividen tahunan?

Cara Menginterpretasikan Data

Penggunaan Data untuk Investasi

Pharma Mar Sejarah Rasio Pembagian Dividen

Pharma Mar Estimasi Pendapatan

Pharma Mar Kejutan Laba

Rating Eulerpool ESG untuk saham Pharma Mar

Eulerpool World ESG Rating (EESG©)

85/ 100

🌱 Environment

👫 Social

🏛️ Governance

Lingkungan (Environment)

Sosial (Social)

Tata Kelola Perusahaan (Governance)

Pharma Mar Struktur Pemegang Saham Aktie

Pharma Mar Dewan Direksi dan Dewan Komisaris

Pertanyaan Umum tentang Saham Pharma Mar

Lakukan investasi terbaik dalam hidupmu
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Pharma Mar Saham
Saham Dividen, Harga, Proyeksi, Forum, Target Harga dan Berita Pharma Mar ariva, Pharma Mar onvista, Pharma Mar finanzen.net, Pharma Mar aktienfinder, Pharma Mar marketscreener, Pharma Mar marketwatch, Pharma Mar bloomberg, Pharma Mar handelsblatt, Pharma Mar wiwo, Pharma Mar forum

Ticker
PHM.MC

ISIN
ES0169501022

WKN
A2P9YT